Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen's Q4 Revenues Rise 80 Percent as Losses Decline 84 Percent

NEW YORK (GenomeWeb News) — Nanogen yesterday said fourth-quarter revenues increased 180 percent as R&D spending remained flat and net losses decreased 84 percent.
Total receipts for the three months ended Dec. 31, 2006, increased to $8.7 million from $3.1 million year over year.
The company said product-related revenue increased around 150 percent to $3.5 million, and income from licensing and royalties increased 65 percent to $2.4 million. Revenue from contracts and grants increased 175 percent to $1.1 million.
R&D spending was flat at $6.6 million compared with $6.4 million year over year.
The company said losses declined to $11.2 million from $69.7 million in the year-ago period.
Nanogen said it had around $11.2 million in cash and equivalents and $13.9 million in short-term investments as of Dec. 31.
The company said it expects revenue to grow more than 50 percent in 2007.  President and COO David Ludvigson said the company expects “solid double digit growth as we achieve milestones” that include submitting assays for the NanoChip 400 with the US Food and Drug Administration and introducing “new, easy to use rapid tests.”

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.